Vivimed Labs Limited (VIVIMEDLAB) Financial History

Name: Vivimed Labs Limited (VIVIMEDLAB) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-20

Vivimed Labs Limited (VIVIMEDLAB) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Hyderabad, India. Its market capitalization is roughly ₹463 million. In the fiscal year ended 2026-03-31, VIVIMEDLAB reported ₹700M in revenue and (₹1.8B) in net income.

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India. It operates through two segments, Speciality Chemicals Business and Pharma Business.

Interactive charts & full statements →

VIVIMEDLAB Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹700M	₹1.2B	₹1.5B	₹1.9B	—
Gross Profit	(₹38M)	₹564M	₹716M	(₹929M)	—
Operating Income (EBIT)	(₹1.8B)	(₹333M)	(₹206M)	(₹2.1B)	—
Net Income	(₹1.8B)	(₹320M)	(₹454M)	(₹3.3B)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VIVIMEDLAB Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31
Total Revenue	₹120M	₹160M	₹206M	₹214M	₹256M	—
Gross Profit	(₹349M)	₹81M	₹115M	₹116M	₹142M	—
Operating Income (EBIT)	(₹1.5B)	(₹156M)	(₹59M)	(₹53M)	(₹80M)	—
Net Income	(₹1.5B)	(₹166M)	(₹73M)	(₹55M)	(₹56M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

VIVIMEDLAB Free Cash Flow History

VIVIMEDLAB Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹7.5B	₹9.2B	₹9.5B	₹10.0B	—
Total Liabilities	₹9.6B	₹9.6B	₹9.6B	₹9.6B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive VIVIMEDLAB viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

MANGALAM · Mangalam Drugs & Organics Limited — ₹542 million
BIOFILCHEM · Biofil Chemicals and Pharmaceuticals Limited — ₹534 million
EVT · Evotec SE — €518 million
KMDA · Kamada Ltd. — $478 million
CGC · Canopy Growth Corporation — $463 million
BIOA · BioAge Labs, Inc. — $421 million
0897 · Wai Yuen Tong Medicine Holdings Limited — HK$384 million
TKNO · Alpha Teknova, Inc. — $372 million

← VIVIDHA All “V” companies VIVK →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.